Key result
Preemptive 25% nadroparin dose reduction achieves target anti-Xa levels in ~51% of renal failure cases.
Why the study?
Does preemptive dosage reduction of nadroparin achieve target anti-Xa activity in patients with renal failure?
Cohort (n=51)
No
Does preemptive dosage reduction of nadroparin achieve target anti-Xa activity in patients with renal failure?
A preemptive 25% dosage reduction of nadroparin in patients with renal failure achieves target anti-Xa activity in only about half of patients, highlighting the need for routine monitoring.
Answers are grounded in this paper and cite their sources.
May require anti-Xa monitoring despite preemptive nadroparin reduction in renal failure; leaves open optimal LMWH dosing strategies.
BACKGROUND: Low-molecular-weight heparins (LMWHs) are frequently used to treat arterial and venous thrombo-embolic events. LMWHs accumulate with renal failure, but only limited clinical data regarding appropriate dosage adjustments are available. Nevertheless, LMWHs are routinely used in these patients worldwide. Although many clinics apply renal function-based dosage reductions, anti-factor Xa (anti-Xa) activity is not measured routinely. METHODS: We determined anti-Xa activity in 51 patients with MDRD-eGFR <60 mL/min/1.73 m(2), treated with therapeutic doses of nadroparin according to a standard, renal function-based guideline. RESULTS: An a priori dosage reduction resulted in anti-Xa activity within, below and above the reference range in 51, 30 and 19% of the measurements, respectively. Treatment resulted in different anti-Xa activities compared with dosages that were not given according to official advice (P < 0.001). Anti-Xa values increased with longer treatment duration (P = 0.038). CONCLUSIONS: A preemptive fixed reduction (25%) of the nadroparin dosage in all patients with renal failure seems appropriate. However, because target anti-Xa activities were reached in only half of the patients, we submit that the use of nadroparin, dosage reduction and monitoring of anti-Xa activity in combination with clinical outcome monitoring in this patient population urgently needs further investigation.
No takes yet. Share an insight, caveat, or question.
Russcher et al. (2013) conducted a cohort in Renal failure (n=51). Nadroparin with preemptive dosage reduction vs. Unadjusted dosages (higher or lower than guideline) was evaluated on Anti-Xa activity within the reference range (0.6-1.0 IE/mL) (p=<0.001). A preemptive 25% dosage reduction of nadroparin in patients with renal failure achieved target anti-Xa activities in 51% of measurements, significantly differing from unadjusted dosages.
Synapse has enriched 10 related papers. Consider them for comparative context: